5,000 patients treated with OssDsign Catalyst® in the U.S.
Uppsala, May 30, 2024. Today, OssDsign AB (publ.) announces that the company continues its successful penetration of the U.S. orthobiologics market. To date, 5,000 patients have been treated with the innovative nanosynthetic bone graft OssDsign Catalyst.The continuous and rapid increase in treated patients is a strong testament to how well OssDsign Catalyst has been received in the U.S. market since its launch in August 2021. “With 5,000 patients treated, the use of OssDsign Catalyst is not just growing, it's accelerating. This is a significant leap from the earlier announcements of